Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study sought to evaluate short-term treatment with COX-2 inhibitors and acute changes in colonic PGE2 levels as predictors of long-term efficacy in a genetic model of colorectal cancer.
|
31797003 |
2020 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Combining clinical factors and COX-2/C-MET/KRAS expression status, our models provided accurate prognostic information in CRC.
|
30720004 |
2020 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression of MIR675-5p or its precursor RNA, H19, correlated with expression of cyclooxygenase-1 and cyclooxygenase-2 and shorter survival times of patients with CRC.
|
31734182 |
2020 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Prognostic significance of EGFR and COX-2 expression in colorectal cancer and their association. A study in Greek population.
|
29552755 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> In conclusion, the overexpression of both c-Myb and COX-2 would be of prognostic screening value in patients with CRC.
|
31205515 |
2019 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Then a GO-based reverse transcription (RT)-LAMP strategy was further developed and applied to detect COX2 mRNA in CRC cancer cells and serum samples with high specificity.
|
31725282 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, COX-2, PGE<sub>2</sub> receptors or Akt represent potential targets in the treatment of CRC, particularly in patients exposed to Cd.
|
31120230 |
2019 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We examined CA IX and COX-2 expression in CRC tissues by immunohistochemical staining of 111 samples.
|
30638861 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of COX-2 and 5-LOX regulates the progression of colorectal cancer by promoting PTEN and suppressing PI3K/AKT pathway.
|
29339153 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study mainly investigated the novel marker IQGAP3 at serum and tumor tissue levels compared with the markers B7-H4 and cyclooxygenase-2 (COX-2) in patients with colorectal cancer (CRC) and in healthy individuals, aiming to evaluate the diagnostic and prognostic value of IQGAP3 for CRC.
|
31223291 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, the present study was designed to assess the prophylactic potentials of probiotics (Lactobacillus acidophilus and Lactobacillus rhamnosus GG) in conjunction with celecoxib, a selective cox-2 inhibitor in 1,2 dimethylhydrazine dihydrochloride (DMH)-induced experimental colon carcinogenesis, a well-established, well appreciated and widely used model for colorectal cancer that shares many similarities to human sporadic colorectal cancer with respect to response to some promotional and preventive agents.
|
30183370 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among them, cyclooxygenase-2 is a prostaglandin-producing hemoprotein, induced during inflammation and in different types of tumor, particularly in colorectal cancer.
|
30941311 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The CRC protective effects of apiaceous vegetables are mainly due to the inhibitory effect of FaOH and FaDOH on NF-κB and its downstream inflammatory markers, especially COX-2.
|
31540047 |
2019 |
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.
|
30826660 |
2019 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Cyclooxygenase-2 (COX-2) is frequently overexpressed and enhances colorectal cancer (CRC) tumorigenesis, including cancer stem cell (CSC) regulation.
|
30480806 |
2019 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
COX-2 expression was positive in 40/49 CRCs, bearing cytoplasmic and heterogeneous staining, from moderate to high intensity.
|
31614548 |
2019 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, epithelial-mesenchymal transition (EMT) phenotype-based subsets of CTCs and the COX-2 expression status in CTCs were identified and their potential clinical values were assessed in 91 CRC patients.
|
30260024 |
2019 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Inflammation and overexpression of cyclooxygenase-2 (COX-2) have been described to play a key role in the progression from nonpathologic intestinal mucosa to colorectal cancer (CRC).
|
31313358 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The CRC condition was produced in response to COX-2 and IL-6 induced activation of JAK2/STAT3 which, in turn, was due to the enhanced phosphorylation of JAK2 and STAT3.
|
29580751 |
2019 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
COX-2 and proliferating cell nuclear antigen (PCNA) expression were assessed immunohistochemically. lncRNA-CCHE1 expression was upregulated in CRC tissues compared to adjacent non-cancerous tissues, and was significantly associated with larger tumor size, less differentiated histology, advanced dukes' stage, positive lymph node involvement and vascular invasion.
|
30484108 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To analyze COX-2 regulation in colorectal cancer and to perform a detailed analysis of their metabolic and proteomic profile.
|
30700940 |
2019 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the COS-treated CRC group (CMCOS), COS protected mice from CRC by decreasing the disease activity index, tumor incidences and multiplicity, and the mRNA levels of COX-2, IL-6, TNF-α, IL-1β, IL-10, and IKK-β mRNA in colonic epithelial cells.
|
31620100 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increased synthesis of PGE<sub>2</sub> in CRC has been shown to occur through COX-2-dependent mechanisms; however, loss of the PGE<sub>2</sub>-catabolizing enzyme, 15-hydroxyprostaglandin dehydrogenase (15-PGDH, HPGD), in colonic tumors contributes to increased prostaglandin levels and poor patient survival.
|
30931980 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> The Adenoma Prevention with Celecoxib (APC) Trial showed that cyclooxygenase-2 (Cox-2) inhibitor, celecoxib, decreased adenoma development in patients at high risk for colorectal cancer.
|
29769213 |
2018 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This review has been written to rediscover the multifaceted potential of PTGS2 targeting, hoping it could act as a starting point for a new and more aware application of NSAIDs against CRC.
|
29421522 |
2018 |